Tower View Wealth Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Tower View Wealth Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-208	Closed	-$109K	–	191
2025 Q2	$109K	Buy	+208	New	+$116K	0.06%	79
2025 Q1	–	Sell	-2,449	Closed	-$1.74M	–	205
2024 Q4	$1.74M	Buy	2,449 +2	+0.1%	+$1.68K	0.92%	42
2024 Q3	$2.57M	Buy	2,447 +136	+6%	+$151K	1.41%	35
2024 Q2	$2.43M	Buy	2,311 +43	+2%	+$41.7K	1.39%	34
2024 Q1	$2.18M	Buy	+2,268	New	+$2.16M	1.28%	36
2021 Q2	–	Sell	-3,819	Closed	-$1.81M	–	194
2021 Q1	$1.81M	Buy	3,819 +581	+18%	+$283K	0.99%	42
2020 Q4	$1.56M	Buy	+3,238	New	+$1.75M	0.89%	43

Other funds holding REGN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Tower View Wealth Management's REGN Position: Q3 2025 in Review

Tower View Wealth Management sold out of Regeneron Pharmaceuticals (REGN) in Q3 2025, closing a stake of 208 shares — an estimated $109K sold.

Tower View Wealth Management first reported a position in REGN in Q4 2020 and held it in 7 quarters. The position peaked at $2.57M in Q3 2024. 1,244 funds tracked by Wall St. Rank hold REGN as of Q3 2025.

Tower View Wealth Management reported no remaining Regeneron Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Tower View Wealth Management sold 208 Regeneron Pharmaceuticals shares in Q3 2025, an estimated $109K.
Tower View Wealth Management first reported a position in Regeneron Pharmaceuticals in Q4 2020 and held it in 7 quarters.
Tower View Wealth Management's Regeneron Pharmaceuticals position peaked at $2.57M in Q3 2024.
1,244 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2025.

Based on Tower View Wealth Management's 13F filing for Q3 2025, filed 16 Oct 2025.